Healthcare provider profile · identity verified

John Benton Crider, M.D.

Allopathic & Osteopathic Physicians|Family Medicine · ARAB, AL · NPI 1528086642

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show John Benton Crider, M.D. received $37.24 in general payments during 2025 across 2 reported records.

SANOFI PASTEUR INC. accounted for 60.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$37.24

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
SANOFI PASTEUR INC.	Unresolved — no canonical attribution shown	$22.42	60.2%	1	2025
Philips North America LLC	Unresolved — no canonical attribution shown	$14.82	39.8%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$37.24	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere	Biological	SANOFI PASTEUR INC.	$22.42	1	2025
Source payment records 2025-02-26 · SANOFI PASTEUR INC. · $22.42 · Open Payments source
FLUZONE HIGH-DOSE Normalized: fluzone high dose	Biological	SANOFI PASTEUR INC.	$22.42	1	2025
Source payment records 2025-02-26 · SANOFI PASTEUR INC. · $22.42 · Open Payments source
Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided	Device	Philips North America LLC	$14.82	1	2025
Source payment records 2025-07-22 · Philips North America LLC · $14.82 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1113	310
Lisinopril	Lisinopril	709	170
Pantoprazole Sodium	Pantoprazole Sodium	647	179
Tramadol Hcl	Tramadol Hcl	594	130
Levothyroxine Sodium	Levothyroxine Sodium	584	136
Losartan Potassium	Losartan Potassium	569	151
Metoprolol Succinate	Metoprolol Succinate	490	115
Amlodipine Besylate	Amlodipine Besylate	432	119
Omeprazole	Omeprazole	402	100
Tizanidine Hcl	Tizanidine Hcl	386	129
Tamsulosin Hcl	Tamsulosin Hcl	363	106
Gabapentin	Gabapentin	333	104
Escitalopram Oxalate	Escitalopram Oxalate	315	86
Potassium Chloride	Potassium Chloride	310	78
Pravastatin Sodium	Pravastatin Sodium	302	76
Methylprednisolone	Methylprednisolone	269	191
Trazodone Hcl	Trazodone Hcl	266	67
Furosemide	Furosemide	262	94
Famotidine	Famotidine	255	89
Metformin Hcl	Metformin Hcl	246	57
Doxycycline Monohydrate	Doxycycline Monohydrate	222	148
Glipizide Er	Glipizide	207	54
Hydrochlorothiazide	Hydrochlorothiazide	206	53
Duloxetine Hcl	Duloxetine Hcl	202	47
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	201	53
Amoxicillin	Amoxicillin	200	136
Azithromycin	Azithromycin	200	149
Fluticasone Propionate	Fluticasone Propionate	168	78
Rosuvastatin Calcium	Rosuvastatin Calcium	147	42
Allopurinol	Allopurinol	145	30
Alendronate Sodium	Alendronate Sodium	143	45
Albuterol Sulfate Hfa	Albuterol Sulfate	139	69
Trulicity	Dulaglutide	137	22
Eliquis	Apixaban	135	27
Metformin Hcl Er	Metformin Hcl	128	37
Warfarin Sodium	Warfarin Sodium	124	15
Ozempic	Semaglutide	122	25
Lorazepam	Lorazepam	121	25
Carvedilol	Carvedilol	115	34
Valsartan	Valsartan	114	25
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	113	77
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	113	25
Clopidogrel	Clopidogrel Bisulfate	112	34
Finasteride	Finasteride	112	38
Bupropion Xl	Bupropion Hcl	106	25
Alprazolam	Alprazolam	104	18
Sertraline Hcl	Sertraline Hcl	104	25
Donepezil Hcl	Donepezil Hcl	103	30
Citalopram Hbr	Citalopram Hydrobromide	98	24
Clonazepam	Clonazepam	97	18
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	97	30
Montelukast Sodium	Montelukast Sodium	96	34
Simvastatin	Simvastatin	93	20
Mirtazapine	Mirtazapine	91	34
Januvia	Sitagliptin Phosphate	86	17
Combivent Respimat	Ipratropium/Albuterol Sulfate	85	20
Humalog Kwikpen U-100	Insulin Lispro	81	19
Jardiance	Empagliflozin	80	15
Synthroid	Levothyroxine Sodium	71	18
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	70	51
Ondansetron Hcl	Ondansetron Hcl	67	42
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	61	27
Oxybutynin Chloride Er	Oxybutynin Chloride	61	15
Memantine Hcl	Memantine Hcl	60	13
Clonidine Hcl	Clonidine Hcl	58	17
Meloxicam	Meloxicam	55	39
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	54	13
Nifedipine Er	Nifedipine	54	11
Fluconazole	Fluconazole	52	34
Glimepiride	Glimepiride	51	22
Mounjaro	Tirzepatide	50	14
Pregabalin	Pregabalin	48	17
Sucralfate	Sucralfate	48	19
Topiramate	Topiramate	48	suppressed
Atenolol	Atenolol	47	13
Esomeprazole Magnesium	Esomeprazole Magnesium	45	12
Spironolactone	Spironolactone	44	14
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	44	13
Metoprolol Tartrate	Metoprolol Tartrate	43	16
Xarelto	Rivaroxaban	43	suppressed
Cefdinir	Cefdinir	41	32
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	41	suppressed
Ropinirole Hcl	Ropinirole Hcl	41	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	40	suppressed
Myrbetriq	Mirabegron	40	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	38	12
Prednisone	Prednisone	38	17
Valacyclovir	Valacyclovir Hcl	38	21
Cephalexin	Cephalexin	35	31
Linzess	Linaclotide	34	12
Clindamycin Hcl	Clindamycin Hcl	33	24
Estradiol	Estradiol	33	suppressed
Fluocinonide	Fluocinonide	33	25
Buspirone Hcl	Buspirone Hcl	32	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	32	20
Fluoxetine Hcl	Fluoxetine Hcl	31	11
Nystatin	Nystatin	31	21
Ciprofloxacin Hcl	Ciprofloxacin Hcl	29	23
Paroxetine Hcl	Paroxetine Hcl	29	suppressed
Celecoxib	Celecoxib	28	13
Meclizine Hcl	Meclizine Hcl	27	13
Telmisartan	Telmisartan	27	suppressed
Colesevelam Hcl	Colesevelam Hcl	26	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	suppressed
Ranolazine Er	Ranolazine	25	suppressed
Diazepam	Diazepam	24	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	24	suppressed
Levofloxacin	Levofloxacin	24	13
Novolog Flexpen	Insulin Aspart	24	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	24	24
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	23	suppressed
Metronidazole	Metronidazole	23	17
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Ramipril	Ramipril	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Irbesartan	Irbesartan	22	suppressed
Klor-Con M10	Potassium Chloride	22	suppressed
Ezetimibe	Ezetimibe	20	suppressed
Premarin	Estrogens, Conjugated	19	suppressed
Terbinafine Hcl	Terbinafine Hcl	19	13
Azelastine Hcl	Azelastine Hcl	18	suppressed
Baclofen	Baclofen	18	suppressed
Levetiracetam	Levetiracetam	18	suppressed
Primidone	Primidone	18	suppressed
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	17	suppressed
Lansoprazole	Lansoprazole	17	suppressed
Oseltamivir Phosphate	Oseltamivir Phosphate	17	17
Propranolol Hcl	Propranolol Hcl	17	suppressed
Silodosin	Silodosin	17	suppressed
Ventolin Hfa	Albuterol Sulfate	17	12
Alfuzosin Hcl Er	Alfuzosin Hcl	16	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Levemir Flexpen	Insulin Detemir	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Carbamazepine	Carbamazepine	15	suppressed
Divalproex Sodium	Divalproex Sodium	15	suppressed
Felodipine Er	Felodipine	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Cefuroxime	Cefuroxime Axetil	14	13
Humalog	Insulin Lispro	14	suppressed
Methocarbamol	Methocarbamol	14	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	14	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	14	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Mupirocin	Mupirocin	13	11
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	12	suppressed
Levetiracetam Er	Levetiracetam	12	suppressed
Phenobarbital	Phenobarbital	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Tiotropium Bromide	Tiotropium Bromide	12	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	12	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	12	suppressed
Carbamazepine Er	Carbamazepine	11	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	11	suppressed
Diltiazem Hcl	Diltiazem Hcl	11	suppressed
Insulin Lispro	Insulin Lispro	11	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$37.24 · 2 records	SANOFI PASTEUR INC.	Ambulatory Monitoring & Diagnostics Undivided, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error